Last reviewed · How we verify
Camyna — Competitive Intelligence Brief
phase 2
tioxolone
Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Carbonic anhydrase 2
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
Camyna (TIOXOLONE). Camyna works by inhibiting the enzyme carbonic anhydrase 2, which helps regulate the balance of acid and base in the body.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Camyna TARGET | TIOXOLONE | phase 2 | tioxolone | Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Carbonic anhydrase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (tioxolone class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Camyna CI watch — RSS
- Camyna CI watch — Atom
- Camyna CI watch — JSON
- Camyna alone — RSS
- Whole tioxolone class — RSS
Cite this brief
Drug Landscape (2026). Camyna — Competitive Intelligence Brief. https://druglandscape.com/ci/tioxolone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing